Literature DB >> 22805774

Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.

Valerie Askanas1, W King Engel, Anna Nogalska.   

Abstract

The pathogenesis of sporadic inclusion-body myositis (s-IBM) is complex; it involves multidimensional pathways and the most critical issues are still unresolved. The onset of muscle fiber damage is age related and the disease is slowly, but inexorably, progressive. Muscle fiber degeneration and mononuclear cell inflammation are major components of s-IBM pathology, but which is precedent and how they interrelate is not known. There is growing evidence that aging of the muscle fiber associated with intramyofiber accumulation of conformationally modified proteins plays a primary pathogenic role leading to muscle fiber destruction. Here, we review the presumably most important known molecular abnormalities that occur in s-IBM myofibers and that likely contribute to s-IBM pathogenesis. Abnormal accumulation within the fibers of multiprotein aggregates (several of which are congophilic and, therefore, generically called "amyloid") may result from increased transcription of several proteins, their abnormal posttranslational modifications and misfolding, and inadequate protein disposal, that is, abnormal "myoproteostasis," which is combined with and may be provoked or abetted by an aging intracellular milieu. The potential cytotoxicity of accumulated amyloid β protein (Aβ42) and its oligomers, phosphorylated tau in the form of paired helical filaments and α-synuclein, and the putative pathogenic role and cause of the mitochondrial abnormalities and oxidative stress are reviewed. On the basis of our experimental evidence, potential interventions in the complex, interwoven pathogenic cascade of s-IBM are suggested.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22805774     DOI: 10.1097/NEN.0b013e31826183c8

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  27 in total

1.  The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo.

Authors:  Alicia N Minniti; Macarena S Arrazola; Marcela Bravo-Zehnder; Francisca Ramos; Nibaldo C Inestrosa; Rebeca Aldunate
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

2.  Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy.

Authors:  Anna Nogalska; Carla D'Agostino; W King Engel; Mafalda Cacciottolo; Shinichi Asada; Kazutoshi Mori; Valerie Askanas
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

3.  Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.

Authors:  Karsten Schmidt; Konstanze Kleinschnitz; Goran Rakocevic; Marinos C Dalakas; Jens Schmidt
Journal:  BMC Neurol       Date:  2016-04-16       Impact factor: 2.474

4.  Demographic and clinical features of inclusion body myositis in North America.

Authors:  A David Paltiel; Einar Ingvarsson; Donald K K Lee; Richard L Leff; Richard J Nowak; Kurt D Petschke; Seth Richards-Shubik; Ange Zhou; Martin Shubik; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2015-02-17       Impact factor: 3.217

5.  Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.

Authors:  Megan K Herbert; Judith Stammen-Vogelzangs; Marcel M Verbeek; Anke Rietveld; Ingrid E Lundberg; Hector Chinoy; Janine A Lamb; Robert G Cooper; Mark Roberts; Umesh A Badrising; Jan L De Bleecker; Pedro M Machado; Michael G Hanna; Lenka Plestilova; Jiri Vencovsky; Baziel G van Engelen; Ger J M Pruijn
Journal:  Ann Rheum Dis       Date:  2015-02-24       Impact factor: 19.103

Review 6.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 7.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

Review 8.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

9.  [New aspects on the pathogenesis of myositis].

Authors:  B Stuhlmüller; E Feist; T Häupl; G-R Burmester; N Pipitone
Journal:  Z Rheumatol       Date:  2013-04       Impact factor: 1.372

Review 10.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.